Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score N/A
- Piotroski Score 3.00
- Grade Neutral
- Symbol (AMYT)
- Company Amryt Pharma plc
- Price $14.70
- Changes Percentage (0%)
- Change -$0
- Day Low $14.70
- Day High $14.71
- Year High $14.71
Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/02/2022
- Fiscal Year End N/A
- Average Stock Price Target $14.50
- High Stock Price Target $14.50
- Low Stock Price Target $14.50
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.37
- Trailing P/E Ratio 39.73
- Forward P/E Ratio 39.73
- P/E Growth 39.73
- Net Income $-18,171,000
Income Statement
Quarterly
Annual
Latest News of AMYT
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Saturday Sessions: Amythyst Kiah performs "Empire Of Love"
Amythyst Kiah, a self-taught singer-songwriter, garnered acclaim for her work in the supergroup "Our Native Daughters." Her latest solo album "Still and Bright" showcases collaborations with notable a...
By CBS News | 1 week ago
